# US 2019/0314546 A1 · Antibiotic polymethylmethacrylate bone cement

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314546 A1
- Document ID: US20190314546A1
- Status: Published application
- Kind: A1
- Application number: 16/432,333
- Filed: 2019-06-05
- Published: 2019-10-17
- Earliest claimed: 2015-12-22
- Assignees: Heraeus Medical GmbH
- Applicants: Heraeus Medical GmbH
- Inventors: SEBASTIAN VOGT; SUSANN KLIMAS
- Web page: https://patentgrep.com/patent/US20190314546A1

## CPC

- A61L 24/06: obtained by reactions only involving carbon-to-carbon unsaturated bonds {(A61L24/043, A61L24/046 take precedence)}
- A61L 24/001: {Use of materials characterised by their function or physical properties}
- A61L 24/0015: {Medicaments; Biocides}
- A61L 27/16: obtained by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/50: Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61P 31/04: Antibacterial agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61L 2300/406: Antibiotics
- A61L 2430/02: for reconstruction of bones; weight-bearing implants
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An antibiotic polymethylmethacrylate bone cement that is composed of methylmethacrylate, at least one polymethylmethacrylate or a polymethylmethacrylate-copolymer, at least one polymerisation initiator, such as in radical initiator, at least one polymerisation accelerator, and at least one radiopaquer, whereby the components are present in a powdered component and a liquid monomer component or in two components that are pasty at room temperature. The polymethylmethacrylate bone cement comprises the cyclical lipopeptide, daptomycin, a pharmacologically tolerable salt of daptomycin, a solvate and/or a hydrate containing daptomycin and at least one calcium salt, which preferably comprises at least two different release profiles. The bone cement is useful in one-stage or two-stage septic revision surgery.

## Claims

### Claim 1

A method of conducting a one-stage or two-stage septic revision surgery, said method comprising anchoring a revision articular endoprosthesis in an area within the human body with an antibiotic bone cement, wherein the antibiotic bone cement is prepared by polymerizing an antibiotic polymerizable bone cement comprising:
(i) at least one monomer for radical polymerisation;
(a2) at least one organic polymer comprising at least one polymethylmethacrylate and/or one polymethylmethacrylate-copolymer, and
(iii) at least one polymerisation initiator;
(iv) at least one radiopaquer;
wherein
the antibiotic polymerizable bone cement comprises,
(v) as component 1, daptomycin, a pharmacologically tolerable salt of daptomycin, a polymorphous form of daptomycin, a solvate and/or a hydrate containing daptomycin; and
(vi) at least one calcium salt.

### Claim 2 (depends on 1)

Method according to claim 1, wherein the polymerizable bone cement comprises, as
(vi) a combination comprising:
a) as component 2, a water-soluble calcium salt possessing a solubility in water at room temperature of more than or equal to 5 g/l; and
b) as component 3, a poorly water-soluble calcium salt possessing a solubility in water at room temperature of less than 5 g/l; and, optionally,
c) at least one of components 1, 2 and/or 3 has a mean particle size of 1 to 250 μm.

### Claim 3 (depends on 1)

Method according to claim 1, which comprises two components A and B, whereby
(i) component A is present as a paste and comprises
(a1) at least one monomer for radical polymerisation;
(a2) at least one organic polymer comprising at least one polymethylmethacrylate and/or one polymethylmethacrylate-copolymer; and
(a3) at least one polymerisation initiator; and
component B is present as a paste and comprises
(b1) at least one monomer for radical polymerisation;
(b2) at least one organic polymer comprising at least one polymethylmethacrylate and/or one polymethylmethacrylate-copolymer; and
(b3) at least one polymerisation accelerator; or
(ii)component A is present as a powder and comprises
(a1) at least one powdered polymer comprising at least one polymethylmethacrylate and/or a powdered mixture comprising polymethylmethacrylate-co-polymers;
(a2) at least one powdered radiopaquer; and
(a3) at least one polymerisation initiator; and
component B is present as a liquid or paste and comprises
(b1) at least one monomer for radical polymerisation;
(b2) optionally, at least one organic polymer comprising at least one polymethylmethacrylate and/or one polymethylmethacrylate-copolymer; and
(b3) at least one polymerisation accelerator; and
whereby at least component A comprises, as
(a4), at least one of components 1, 2, and 3 selected from component 1 daptomycin, a pharmacologically tolerable salt of daptomycin, a solvate and/or a hydrate containing daptomycin, component 2 a water-soluble calcium salt possessing a solubility in water at room temperature of more than or equal to 5 g/l and component 3 a poorly water-soluble calcium salt possessing a solubility in water at room temperature of less than 5 g/l, and/or
whereby component B is present as a paste and comprises, as
(b4), at least one of components 1, 2, and 3 selected from component 1 daptomycin, a pharmacologically tolerable salt of daptomycin, a polymorphous form of daptomycin, a solvate and/or a hydrate containing daptomycin, component 2 a water-soluble calcium salt possessing a solubility in water at room temperature of more than or equal to 5 g/l, and component 3 a poorly water-soluble calcium salt possessing a solubility in water at room temperature of less than 5 g/l.

### Claim 4 (depends on 1)

Method according to claim 1, wherein
(v) component 1 daptomycin, a pharmacologically tolerable salt of daptomycin, a polymorphous form of daptomycin, a solvate and/or a hydrate containing daptomycin, and (vi) a) component 2 the water-soluble calcium salt possessing a solubility in water at room temperature of more than or equal to 5 g/l, and b) component 3 the poorly water-soluble calcium salt possessing a solubility in water at room temperature of less than 5 g/l, each independently is present in the form of particles of components 1, 2 or 3 or each independently is a particulate formulation containing, each independently, at least one of components 1, 2 and/or 3, and at least one pharmacological excipient and, optionally, each independently comprise a mean particle size of 1 to 250 μm.

### Claim 5 (depends on 1)

Method according to claim 1, wherein at least component A comprises, as
(a4), at least one of components 1, 2, and 3, which each independently are present in the form of particles of components 1, 2 or 3 or each independently, as a particulate formulation, containing, each independently, at least one of components 1, 2 and/or 3 and, optionally, each independently comprise a mean particle size of 1 to 250 μm,
whereby component B is present as a paste and comprises, as (b4) at least one of components 1, 2, and 3, which each independently are present in the form of particles of components 1, 2 or 3 or each independently, as a particulate formulation, containing, each independently, at least one of components 1, 2 and/or 3 and, optionally, each independently comprise a mean particle size of 1 to 250 μm.

### Claim 6 (depends on 1)

Method according to claim 1, wherein
a) the polymerizable bone cement is present, as (a4) and/or (b4), as particles of a combination at least of components 1 and 2 or, each independently, as a particulate formulation containing at least a combination of components 1 and 2 and at least one pharmacological excipient; or
b) the polymerizable bone cement is present, as (a4) and/or (b4), as particles of a combination of components 1, 2, and 3 or, each independently, as a particulate formulation containing the combination of components 1, 2, and 3 and at least one pharmacological excipient.

### Claim 7 (depends on 2)

Method according to claim 2, wherein
a) component 2, the water-soluble calcium salt possessing a solubility in water at room temperature of more than or equal to 5 g/l, comprises calcium gluconate, calcium glucuronate, calcium lactate, calcium acetate and/or calcium sorbate or a mixture containing at least two of said calcium salts.

### Claim 8 (depends on 2)

Method according to claim 2, wherein
b) component 3 the poorly water-soluble calcium salt possessing a solubility in water at room temperature of less than 5 g/l, comprises calciumsulfate-dihydrate, calciumsulfat-hemihydrate, alpha-tricalciumphosphate and/or beta-tricalciumphosphate.

### Claim 9 (depends on 1)

Method according to claim 1, which contains at least one second antibiotic selected from the group of the aminoglycoside antibiotics and/or the lincosamide antibiotics and/or the ansamycin antibiotics and/or the fluoroquinolone antibiotics and/or the β-lactam antibiotics.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the area within the human body has been subjected to radical debridement after explantation of an infected articular endoprosthesis.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the infected articular endoprosthesis is infected with gram-positive bacteria.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the gram-positive bacteria is selected from the group consisting of methicillin-resistant staphylococci and vancomycin-resistant staphylococci.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the gram-positive bacteria is selected from the group consisting of vancomycin-resistant staphylococci.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the antibiotic bone cement is adapted to provide synchronous release of daptomycin and calcium ions over a period of several days.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the antibiotic bone cement is in the form of a revision implant, screw, nail, or surgical plate used to mechanically fix the revision articular endoprosthesis in place.

### Claim 16

A method of conducting a one-stage or two-stage septic revision surgery, said method comprising removing an infected articular endoprosthesis from an area within the human body and temporarily introducing a spacer into that area, wherein the spacer is composed of an antibiotic bone cement prepared by polymerizing an antibiotic polymerizable bone cement comprising:
(i) at least one monomer for radical polymerisation;
(a2) at least one organic polymer comprising at least one polymethylmethacrylate and/or one polymethylmethacrylate-copolymer; and
(iii) at least one polymerisation initiator;
(iv) at least one radiopaquer;
wherein
the antibiotic polymerizable bone cement comprises,
(v) as component 1, daptomycin, a pharmacologically tolerable salt of daptomycin, a polymorphous form of daptomycin, a solvate and/or a hydrate containing daptomycin; and
(vi) at least one calcium salt.

### Claim 17 (depends on 16)

Method according to claim 16, wherein the polymerizable bone cement comprises, as
(vi) a combination comprising:
a) as component 2, a water-soluble calcium salt possessing a solubility in water at room temperature of more than or equal to 5 g/l; and
b) as component 3, a poorly water-soluble calcium salt possessing a solubility in water at room temperature of less than 5 g/l; and, optionally,
c) at least one of components 1, 2 and/or 3 has a mean particle size of 1 to 250 μm.

### Claim 18 (depends on 16)

Method according to claim 16, which comprises two components A and B, whereby
(i) component A is present as a paste and comprises
(a1) at least one monomer for radical polymerisation;
(a2) at least one organic polymer comprising at least one polymethylmethacrylate and/or one polymethylmethacrylate-copolymer; and
(a3) at least one polymerisation initiator; and component B is present as a paste and comprises
(b1) at least one monomer for radical polymerisation;
(b2) at least one organic polymer comprising at least one polymethylmethacrylate and/or one polymethylmethacrylate-copolymer; and
(b3) at least one polymerisation accelerator; or
(ii)component A is present as a powder and comprises
(a1) at least one powdered polymer comprising at least one polymethylmethacrylate and/or a powdered mixture comprising polymethylmethacrylate-co-polymers;
(a2) at least one powdered radiopaquer; and
(a3) at least one polymerisation initiator; and
component B is present as a liquid or paste and comprises
(b1) at least one monomer for radical polymerisation;
(b2) optionally, at least one organic polymer comprising at least one polymethylmethacrylate and/or one polymethylmethacrylate-copolymer; and
(b3) at least one polymerisation accelerator; and
whereby at least component A comprises, as
(a4), at least one of components 1, 2, and 3 selected from component 1 daptomycin, a pharmacologically tolerable salt of daptomycin, a solvate and/or a hydrate containing daptomycin, component 2 a water-soluble calcium salt possessing a solubility in water at room temperature of more than or equal to 5 g/l and component 3 a poorly water-soluble calcium salt possessing a solubility in water at room temperature of less than 5 g/l, and/or whereby component B is present as a paste and comprises, as
(b4), at least one of components 1, 2, and 3 selected from component 1 daptomycin, a pharmacologically tolerable salt of daptomycin, a polymorphous form of daptomycin, a solvate and/or a hydrate containing daptomycin, component 2 a water-soluble calcium salt possessing a solubility in water at room temperature of more than or equal to 5 g/l, and component 3 a poorly water-soluble calcium salt possessing a solubility in water at room temperature of less than 5 g/l.

### Claim 19 (depends on 16)

Method according to claim 16, wherein
(v) component 1 daptomycin, a pharmacologically tolerable salt of daptomycin, a polymorphous form of daptomycin, a solvate and/or a hydrate containing daptomycin, and (vi) a) component 2 the water-soluble calcium salt possessing a solubility in water at room temperature of more than or equal to 5 g/l, and b) component 3 the poorly water-soluble calcium salt possessing a solubility in water at room temperature of less than 5 g/l, each independently is present in the form of particles of components 1, 2 or 3 or each independently is a particulate formulation containing, each independently, at least one of components 1, 2 and/or 3, and at least one pharmacological excipient and, optionally, each independently comprise a mean particle size of 1 to 250 μm.

### Claim 20 (depends on 16)

Method according to claim 16, wherein at least component A comprises, as
(a4), at least one of components 1, 2, and 3, which each independently are present in the form of particles of components 1, 2 or 3 or each independently, as a particulate formulation, containing, each independently, at least one of components 1, 2 and/or 3 and, optionally, each independently comprise a mean particle size of 1 to 250 μm,
whereby component B is present as a paste and comprises, as (b4) at least one of components 1, 2, and 3, which each independently are present in the form of particles of components 1, 2 or 3 or each independently, as a particulate formulation, containing, each independently, at least one of components 1, 2 and/or 3 and, optionally, each independently comprise a mean particle size of 1 to 250 μm.

### Claim 21 (depends on 16)

Method according to claim 16, wherein
a) the polymerizable bone cement is present, as (a4) and/or (b4), as particles of a combination at least of components 1 and 2 or, each independently, as a particulate formulation containing at least a combination of components 1 and 2 and at least one pharmacological excipient; or
b) the polymerizable bone cement is present, as (a4) and/or (b4), as particles of a combination of components 1, 2, and 3 or, each independently, as a particulate formulation containing the combination of components 1, 2, and 3 and at least one pharmacological excipient.

### Claim 22 (depends on 17)

Method according to claim 17, wherein
a) component 2, the water-soluble calcium salt possessing a solubility in water at room temperature of more than or equal to 5 g/l, comprises calcium gluconate, calcium glucuronate, calcium lactate, calcium acetate and/or calcium sorbate or a mixture containing at least two of said calcium salts.

### Claim 23 (depends on 17)

Method according to claim 17, wherein
b) component 3 the poorly water-soluble calcium salt possessing a solubility in water at room temperature of less than 5 g/l, comprises calciumsulfate-dihydrate, calciumsulfat-hemihydrate, alpha-tricalciumphosphate and/or beta-tricalciumphosphate.

### Claim 24 (depends on 16)

Method according to claim 16, which contains at least one second antibiotic selected from the group of the aminoglycoside antibiotics and/or the lincosamide antibiotics and/or the ansamycin antibiotics and/or the fluoroquinolone antibiotics and/or the β-lactam antibiotics.

### Claim 25 (depends on 16)

The method according to claim 16, wherein the area within the human body has been subjected to radical debridement after explantation of an infected articular endoprosthesis.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the infected articular endoprosthesis is infected with gram-positive bacteria.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the gram-positive bacteria is selected from the group consisting of methicillin-resistant staphylococci and vancomycin-resistant staphylococci.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the gram-positive bacteria is selected from the group consisting of vancomycin-resistant staphylococci .

### Claim 29 (depends on 16)

The method according to claim 16, wherein the antibiotic bone cement is adapted to provide synchronous release of daptomycin and calcium ions over a period of several days.
